586 related articles for article (PubMed ID: 27163152)
1. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
2. Denosumab: Current Use in the Treatment of Primary Bone Tumors.
Savvidou OD; Bolia IK; Chloros GD; Papanastasiou J; Koutsouradis P; Papagelopoulos PJ
Orthopedics; 2017 Jul; 40(4):204-210. PubMed ID: 28732103
[TBL] [Abstract][Full Text] [Related]
3. Chondroblastoma Expresses RANKL by RNA In Situ Hybridization and May Respond to Denosumab Therapy.
Suster DI; Kurzawa P; Neyaz A; Jarzembowski JA; Lozano-Calderon S; Raskin K; Schwab J; Choy E; Chebib I; Deshpande V
Am J Surg Pathol; 2020 Dec; 44(12):1581-1590. PubMed ID: 32826531
[TBL] [Abstract][Full Text] [Related]
4. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
5. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
7. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
8. Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.
Wojcik J; Rosenberg AE; Bredella MA; Choy E; Hornicek FJ; Nielsen GP; Deshpande V
Am J Surg Pathol; 2016 Jan; 40(1):72-80. PubMed ID: 26414220
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
10. Denosumab Induces Neoplastic Stromal Cell Apoptosis
Chen X; Ye F; He H; Chen G; Chen Z; Ye E; He B; Yang Y; Zhang J
Curr Cancer Drug Targets; 2024; 24(5):565-578. PubMed ID: 37961860
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment.
Noguchi T; Sakamoto A; Murotani Y; Murata K; Hirata M; Yamada Y; Toguchida J; Matsuda S
J Histochem Cytochem; 2023 Mar; 71(3):131-138. PubMed ID: 36971322
[TBL] [Abstract][Full Text] [Related]
12. Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern.
Stagner AM; Sajed DP; Nielsen GP; Ebb DH; Faquin WC; Chebib I; Rivera MN; Ting DT; Resnick CM; Peacock ZS; Kaban LB; Deshpande V
Am J Surg Pathol; 2019 Jun; 43(6):819-826. PubMed ID: 30998511
[TBL] [Abstract][Full Text] [Related]
13. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone.
Cowan RW; Singh G; Ghert M
J Orthop Res; 2012 Jun; 30(6):877-84. PubMed ID: 22102368
[TBL] [Abstract][Full Text] [Related]
14. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
[TBL] [Abstract][Full Text] [Related]
15. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
16. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
Yamamoto H; Ishihara S; Toda Y; Oda Y
Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
[TBL] [Abstract][Full Text] [Related]
17. Denosumab Treatment for Giant Cell Tumors, Aneurysmal Bone Cysts, and Fibrous Dysplasia-Risks and Benefits.
Pan KS; Boyce AM
Curr Osteoporos Rep; 2021 Apr; 19(2):141-150. PubMed ID: 33616817
[TBL] [Abstract][Full Text] [Related]
18. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
[TBL] [Abstract][Full Text] [Related]
19. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.
Wu PF; Tang JY; Li KH
Tumour Biol; 2015 Feb; 36(2):495-501. PubMed ID: 25618600
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for the treatment of giant cell tumor of the bone.
Brodowicz T; Hemetsberger M; Windhager R
Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]